BioPortfolio Limited Business Insights

Innovative Strategies and Models for R&D Success: The evolving networked pharma company
Many pharma companies are currently engaged in wide-scale R&D restructuring, adopting a biotechnological approach to drug development by establishing disease-focused R&D units, R&D spin-offs, strategic partnerships and joint ventures. This trend has been reinforced by the emergence of public/private partnerships, co-operatives and open-source research initiatives that have encouraged companies to target previously neglected disease areas such as biotherapeutics and vaccines. Emerging markets are also driving change throughout R&D, with companies increasingly internationalizing their processes to take advantage of tax incentives, government investment, cheap labor and technology specialists.

Innovations and Pipelines for Respiratory Disorders: Niche markets, new products and future developments
The market for respiratory disorder treatments is continuing to experience rapid expansion as healthcare payors increasingly acknowledge the high treatment costs associated with chronic indications. A shift in developmental focus has become the driving force for market transformation, with research efforts now targeting the causative disease pathway in an effort to prevent symptom presentation and pathological decline. In the short term, a number of impending product launches will satisfy unmet demand within high-value market niches by addressing issues of patient compliance and targeting patients at the more severe end of the disease spectrum.

The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
The Global Anti-infectives Market Outlook to 2013 provides comprehensive coverage of the anti-infectives market, incorporating the disease overview and detailed epidemiological analysis of the major indications. This report analyzes the marketed product portfolio, in-depth R&D pipeline analysis, market share data, sales forecast and the competitive landscape for the major players.

August 2008 Format PDF

The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses
The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbuster drugs are the primary growth driver of the industry.

Rising healthcare expenditure has also contributed to industry expansion, with governments coming under growing pressure to provide low cost alternatives to branded drugs. However, the generics market is changing due to the threat from authorized generics, competition from players in emerging countries and increasing consolidation. Teva’s acquisition of Barr Pharmaceuticals is the latest example of companies attempting to improve their market strength and geographical reach via divestments and acquisitions.

Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies
Developing, manufacturing and marketing innovative new pharmaceutical drugs is highly complex and involves significant investment. Establishing an acceptable return on investment requires generating sufficient sales revenues which in turn requires maximizing market access at the highest possible price.

Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
The rising prevalence of obesity is a growing problem in developed countries, with 32% of Americans and 17% of EU residents considered obese in 2008. The condition is associated with a range of severe co-morbidities, the most significant of which include asthma, cardiovascular disease, cancer, diabetes, hypertension and kidney disease. Obesity-related treatments cost healthcare payors billions of dollars each year, and the market for medications is steadily expanding as incidence of obesity continues to increase. Stringent regulations have restricted the amount of medications currently available, however many currently marketed products are failing to meet consumer needs. Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment is a new report published by Business Insights that explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area. The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products. Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report.

Contract Manufacturing Strategies - Market developments, technology transfer and key success factors
Drug manufacture now typically accounts for 25% of company revenues and achieving agility in the manufacturing process has become essential for pharma companies hoping to align their supply chains with constant shifts in global product demand. In addition to offering efficiencies in cost, capacity and time-to-market, contract manufacturing organizations (CMOs) can provide innovative, state-of-the-art process and production technologies to support the rapid technical transfer of products from R&D to commercial manufacturing. However, the effective management of the CMO/sponsor relationship is critical not only in satisfying regulatory requirements amid growing concerns over quality control, but also in meeting the overall commercial aim of the project. ’Contract Manufacturing Strategies’ is a new report published by Business Insights that explores the future of the contract manufacturing market with a detailed analysis of emerging drivers and restraints, business models and production strategies. The potential benefits and risks of contract manufacturing are assessed and the key strategies for effective CMO selection and successful relationship management are identified. This report also reviews the latest FDA contract legislation to determine the most effective measures in ensuring regulatory compliance and assesses the rapidly expanding markets of India and China in terms of growth potential and regulatory outlook. Understand how the CMO market will develop over the 2008-13 period, identify emerging manufacturing strategies and regulatory developments and assess the outsourcing growth potential of India and China.

The Emerging Role of Postmarketing Clinical Research - Regulatory issues, strategic drivers and overall trends
The pharmaceutical industry has recently endured intense speculation and negative publicity as a result of high profile product withdrawals caused by inadequate safety profiles. Regulatory bodies have responded swiftly; the FDA now requires mandatory surveillance data submission for drugs under increased scrutiny, and the EMEA is close to implementing similar strategies as part of drug policy harmonization initiatives for phase IV trials.

Innovative Clinical Trial Design and Management - Trends, success stories and impact upon R&D budgets
The costs associated with developing drugs have risen dramatically over the past decade and fewer drugs are obtaining regulatory approval. The pharmaceutical industry is continually exploring new ways of improving drug developments and one area of focus is adaptive clinical trial designs. These innovative clinical trial designs use accumulating data to guide potential modifications to the study as it progresses, without undermining the validity and integrity of the trial. The advantages of such designs include the reduced length and cost of clinical trials, lower patient numbers and the ability to stop a trial early where a drug has not shown efficacy.

Innovations in The Management of Diabetes - Next generation treatments and market dynamics
Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
Leading Drug Delivery Companies and Technologies

Competitive landscape, company profiles and technological developments

Business Intelligence for the Pharmaceutical Industry

The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
In recent years, there have been concerted efforts to enhance the precision of disease diagnosis and monitoring as the hetrogeneity of conditions becomes increasingly understood. Targeting broad patient populations in a ‘one-pill-fits-all’ approach has begun to attract criticism, with the average efficacy of such drugs being estimated at 50% or less. In the current climate, biomarkers have emerged as key tools in the realisation of personalised medicine by characterizing specific diseases and treatment responses at the DNA, RNA, protein, or metabolite level.

Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
Drug safety has become a major industry concern following the market withdrawal of Merck’s Vioxx in 2004 and several other discontinuations of COX-2 inhibitors. Although adverse reactions were previously considered a relatively minor risk compared to a drug’s wider benefit, both newly approved and established drugs are now under intense scrutiny. Drug approvals in the US and Europe have become subject to approval delays, rising requests for further clinical data, and greater chances of rejection. Regulators are currently attempting to reconfigure review processes in order to minimize delays in recognition of the potential mass benefits of new applications Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response is a new report published by Business Insights that provides a comprehensive review of current drug approval trends in the US and Europe with case studies highlighting successful and unsuccessful applications. Emerging regulatory developments and process improvements are examined and the strategic measures implemented by developers to enhance the approval potential of their drugs are assessed. This report also evaluates the future regulatory landscapes of the FDA and EMEA, with a review of anticipated developments through to 2012. Understand the changing landscape for FDA and EMEA drug approvals, discover the implications of process overhauls upon your drug applications and anticipate future regulatory developments with this new report.

The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare industry. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis cross-company collaborations and the exchange of information. However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies. The Fastest Growing Biopharmaceutical Companies: Growth strategies, comparative analysis and company profiles is a new report published by Business Insights that examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biopharmaceutical companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry. Use key indicators to assess the performances of the fastest growing biopharma companies, benchmark their most successful strategies and understand major industrial issues with this new report.

Impact of Pharmacogenomics on Public Healthcare Policy Educating patients, payors and healthcare providers
During the last fifteen years tremendous advances have been made in deciphering the genetic coding of a variety of species from invertebrates, vertebrates and finally man through the formal initiation of the Human Genome Project in October 2000 and its completion in 2003. This information has helped to increase our understanding of how genetics has a pivotal role in the predisposition of many diseased states, the progression of a course of a disease, as well as a patient’s response to a drug, or lack of it. Now in the 21st Century there is a growing trend towards the development of personalized medicine – the right drug for the right individual.

The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules. The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry.

Heart Health Food and Drinks NPD in cardiovascular health, hypertension and cholesterol reduction
The heart health food and drinks market has seen continued development and a generation of products targeting specific conditions such as blood pressure and cholesterol reduction, have been the focus of innovation. However, the market is beginning to shift again, this time towards more ‘natural’ heart health products which promote an overall, holistic and everyday approach to heart health. Heart Health Food and Drinks is a new management report published by Business Insights that analyzes the underlying growth drivers for the heart health foods and drinks market, assesses future sales prospects in key geographical markets, reviews the latest innovations trends and offers actionable recommendations for food and drinks manufacturers. It examines the latest actual and forecast data for hypertension and cardiovascular disease prevalence, heart health food and drinks sales values, as well as unique data on product innovations for all the key product groups. Develop more effective strategies for heart healthy food and drinks using this report’s analysis of the development of the market by country and product category.

Nanotechnology Revolutionizing R&D to develop smarter therapeutics and diagnostics
Nanotechnologies have already attracted over $3bn of global government funding as part of efforts to enhance a range of disciplines including pharmaceuticals, drug delivery and healthcare monitoring. Advances in nanomaterials, nanostructures and nanosystems are expected to drive the value of the global nanotehnology market to over a trillion dollars by 2015, but many companies are remaining cautious, preferring to monitor developments in academia prior to making substantial investments. Despite such trepidation, the pharma industry is beginning to adopt nanotools throughout the R&D process to facilitate the high throughput screening of drug repositories, the identification of new drug targets and biomarkers for preclinical and clinical studies and the development of diagnostics and imaging agents. ‘Nanotechnology’ is a new report published by Business Insights that provides a comprehensive review of nanotechnology and it’s role in the development of next-generation nanomedicines. The nanotools and detection systems currently driving nanotechnology are profiled and the applications of nanotechnologies within the R&D process are assessed. This report measures the impact of nanotechnologies currently being applied to target cancer, cardiovascular disease and CNS disorders and also explores the implementation strategies of leading pharmaceutical, healthcare and nanotechnology start-ups. Use this new report to assess the future of nanotechnology within pharma R&D, identify the innovations driving growth within the market and examine the implementation strategies of leading companies.

Innovations in Bioinformatics Emerging tools for drug discovery and development
R&D laboratories are co-ordinating the analysis of increasing volumes of disparate biological data, largely comprised of gene and protein sequences. Bioinformatics-enabled data management has enabled companies to improve productivity within their R&D programmes by identifying new drug targets, diagnostic biomarkers and biomarkers of drug efficacy and toxicity. From a systems biology approach, bioinformatics combine data into interactive models to highlight disease pathways and aid the discovery of on off-target effects of compounds. Knowledge management solutions are crucial in both instances, enabling project teams to make informed decisions about potential new drugs. ‘Innovations in Bioinformatics’ is a new report published by Business Insights that provides a detailed analysis of bioinformatic developments and applications. This report examines the bioinformatic tools used to manage high-throughput data from omic technologies, systems biology modelling and biomarker discovery. Knowledge management solutions are reviewed and the provisions of major bioinformatics contributors are highlighted. This report also provides forecasts for bioinformatic tools and services to 2011. Use this new report to identify the latest developments in bioinformatics, assess the tools and platforms that can improve drug developments and benchmark effective implementation strategies.

The Cardiovascular Disorders Market Outlook to 2012
The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches. With product launches in mainstream cardiovascular indications facing continued difficulties, major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios underperform. The Cardiovascular Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth. Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report...

Launching Combination Products: Brand extension and franchise development strategies
Combination pharmaceutical products, or fixed-dose combinations (FDC’s), offer benefits to many drug classes due to the additive nature of therapeutic effect and the reduced level of side-effects associated with their use. Their core advantage however is an improvement in convenience that stems from reducing prescription numbers and their associated administrative costs.

The Cancer Market Outlook to 2012
Medicines in the cancer therapeutic area account for the third largest source of revenue within the pharma industry. The cancer market has experienced significant innovative change in recent years, creating attractive opportunities for a range of new and established biotechnology players as well as established pharma companies. Although new product development continues to involve substantial levels of risk, innovation is the key driving force in the market, and has led to the competitive exclusion of several of the industry’s traditional competitors. With successful launches now being applied to multiple indications faster than ever before, subsequent increases in product sales volumes are rapidly changing the competitive landscape of the cancer market. The Cancer Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 9 % of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2 6-12 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.

Published: January 2008 - Global.

Lifestyle Drugs Market Outlook Key Indications, Epidemiology, and Emergent Drugs
The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry. With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding activity, conditions appear highly favourable for further growth. ‘Lifestyle Drugs Market Outlook’ is a new report published by Business Insights that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management. Key industrial trends in the fields of consumer demand and pipeline development are examined, leading players and products within each treatment area are profiled and the market potential of each lifestyle therapy is assessed. This report will also provide a substantial review of reimbursement policies within the seven major markets and their impact upon product sales.

Optimizing Partnerships with Contract Organizations Effective management, key issues and the development of virtual pharmacos
Business Insights' portfolio of pharmaceutical outsourcing management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques.

Immunomodulators - Therapeutic Needs, Pipelines & Prospects
The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures. With traditional immunomodulatory drugs continuing to exhibit limited efficacy and adverse side effects, the drive to develop new, improved, and specifically targeted immunotherapies has been gaining momentum.

Drug Development Opportunities in China - Regulation, key players and initiatives for domestic and international markets
Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance. Human clinical studies have historically dominated outsourced R&D activities in China, with the country’s relative lack of capital and expertise being insufficient to facilitate technologically intensive discovery and pre-clinical work.

Translational Medicine in Biopharmaceutical R and D - Enabling R and D optimization and early detection of potential failures
As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research. Translational science has emerged as a concept that is set to revolutionise the traditional R&D paradigm by integrating drug discovery and development, areas with previously limited interaction.

Biomanufacturing Strategies - Market drivers, build-vs-buy decisions and opportunities in contract relationship management
The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20. The proportion of biologics in new drug approvals has risen by over 30% during the last decade, and with the current pipeline containing more than 500 protein and 50 peptide developmental drugs, this trend is set to continue. The commercial success of over 350 approved biologics has prompted the biotechnology industry to accelerate discoveries in further protein-based therapeutics, placing greater emphasis upon the importance of biomanufacturing. Many biotechnology companies are faced with limited resources, and as large-scale manufacturing continues to intensify, deciding whether it should be internalised or outsourced to partners or CMO’s is increasingly crucial in the development of a biotech firm.

Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets in areas such as cancer and infectious diseases. Since 2005, enormous strides have also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.

‘Outlook for RNAi 2007’ is a new report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process. It puts into context where RNAi technology is being used as a tool of choice within academia and the pharma industry for functional genomic studies, drug target discovery and mechanism of action studies. The development status RNAi based therapeutics is covered in detail, highlighting the key companies in the field, outlining their pipelines and describing the results of completed clinical trials.

Pharmaceutical Pricing and Reimbursement Strategies for market access across the US, Europe, Japan and other key geographies
The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns.

The Gastrointestinal Market Outlook to 2012
As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs.

The CNS Market Outlook to 2012
CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer’s and Parkinson’s disease.

Emerging Pharmaceutical Markets Growth opportunities, changing healthcare dynamics and regulatory trends
The growth of emerging pharmaceutical markets remains impressively buoyant, having attained a 14.7% value increase over the 2005-06 period, a substantially greater rate than those witnessed within the developed markets of the EU and US. Although emergent markets proffer access to sizeable patient populations, significant barriers to entry continue to exist.

Innovations in Cardiovascular Disease Management Latest surgical procedures drugs and medical devices
Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. ‘Innovations in Cardiovascular Disease Management’ is a new report published by Business Insights that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities.

The Future of Biosimilars Key opportunities and emerging therapies
Biotechnological products are continuing to exhibit substantial revenue gains, with the top 12 biologics registering sales growth of 20%in 2006, amassing a market share of $64 billion. However, the impending patent expiry of many leading products has created a number of highly attractive market opportunities for biosimilars. To exploit this significant potential, a complex route to market must first be negotiated, including numerous barriers to entry and regulatory hurdles. Prominent obstacles include the sizeable investments in time and expertise associated with biosimilars development, in addition to the fundamentally higher levels of cost and risk incurred by manufacturers. Legislative restraints in the US and a recently established regulatory framework in the EU have also contributed to industrial obtrusiveness, but for those developers who persevere, biosimilars are set to offer lucrative returns. The Future of Biosimilars: Key opportunities and emerging therapies is a new report published by Business Insights, examining the current market and regulatory environment for biosimilars in Europe, India, China and the US, whilst identifying the trends that will shape future market development.

Autoimmune Market Outlook to 2012
Autoimmune related disorders continue to maintain prominence within the global disease burden, having achieved a worldwide market growth of 9.4% over the 2002-06 period. However, the inherent threat of generic competition and novel product launches are forecast to transform the dynamics of the autoimmune market over the next 5 years. The autoimmune pipeline represents a key opportunity for drug development companies, with the potential for success largely attributable to substantial unmet demand, a significant patient population and the medical proclivity for long term treatments. In consequence, the effective exploitation of market potential is becoming increasingly crucial, and hinges upon drug developments that accurately reflect the shifting demographics of autoimmune disorders and unmet patient needs. Autoimmune Market Outlook to 2012 is a new report published by Business Insights, examining how the competitive dynamics of major pharma companies will influence the market positions of products and shape the direction of future global autoimmunology. Market trends and leading brands of treatment are extensively profiled, while the most commercially promising R&D therapies are investigated and assessed to discover their sales potential. This report will also provide a comprehensive epidemiological analysis of the major indications and detailed product sales forecasts. Use this report to identify opportunities in the autoimmune pipeline, assess the dynamics of leading competitors and evaluate the impact of key trends across the global market.

Patent Protection Strategies Maximising product Revenues
In a market environment where competition from generics companies is becoming increasingly aggressive, and the patenting of therapeutics is continually subject to impending legislative change, understanding how to effectively reassess, develop and exploit patent protection strategies is essential in facilitating enhanced market exclusivity and revenue returns over the lifecycles of new drugs. Patent Protection Strategies: Maximising product revenues is a new report published by Business Insights that examines the need for optimising and sustaining the patent protection of novel products. The best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations are also explored. It will also investigate both the offensive and defensive tactics that can develop product lifecycle strategies, through the refinery of organisational patent protection in tandem to encumbering the market entry of generic substitutes. Develop and apply successful patent protection strategies, exploit legislation effectively and secure the lifecycles of your innovations with this new report

The Global HIV/AIDS Market Outlook to 2012
Shifting epidemiological demographics within the HIV marketplace, increasing resistance to current therapies and unmet needs within the patient population...only an intrinsic understanding of these issues can secure the commercial success of new drug developments. ‘The Global HIV/AIDS Market Outlook to 2012’ is a new management report published by Business Insights that provides comprehensive coverage of the global HIV/AIDS market, incorporating a detailed epidemiological analysis of the prevalence of HIV/AIDS and key factors impacting prevalence in both the seven major pharmaceutical markets as well as emerging markets. This report analyses current leading brands of treatment within the HIV market, provides invaluable insights into market dynamics, profiles the leading pharmaceutical companies and details the key market trends influencing product sales. This new report will enable you to plan more effectively, evaluate key changes in the competitive landscape and identify potential growth areas in the global HIV/AIDS market.

Drug Repositioning Strategies Innovative strategies to boost pipeline productivity
Report overview Key findings

Drug repositioning is regarded as the pharma industry’s solution to falling R&D productivity and weakening product pipelines, successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabledinnovative companies to adopt lower risk strategies to optimize product pipelines. Drug Repositioning Strategies is a new report that provides in-depth analysis of leading pharma companies that are using novel technologies to reposition failed, marketed or reformulated compounds. This report analyzes strategies that are currently being employed by the leading players and the associated opportunities and challenges arising from them, enabling you to understand trends in the market and optimize your R&D pipeline. Use this report to examine current approaches to drug repositioning and identify successful technologies and business models that can help your organization deliver enhanced clinical and commercial output.

Innovative and Targeted Cancer Therapies Key technologies new applications and leading players
The highly dynamic cancer market is creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. Resultantly, cancer innovatives are not only the fastest growing segment within the cancer market, but the key drivers of sales growth across the pharmaceutical market as a whole.

The Indian Pharmaceutical Market to 2011 Competitive dynamics and major players
Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth.

The Global Anti-Infectives Market Outlook to 2011
The anti-infectives market is forecast to expand at a CAGR of 4.8%over the period 2005-11, driven largely by gains in the anti-bacterial and anti-viral classes. This represents significant market opportunity for pharma companies to expand their sales potential by targeting high growth markets. ‘The Global Anti-Infectives Market Outlook to 2011’ provides comprehensive coverage of the anti-infectives market, incorporating a detailed epidemiological analysis of the major indications and the key factors impacting their prevalence. Analysis of the major brands and profiles of the leading pharmaceutical companies will ensure that you can plan effectively, evaluate key changes in the competitive landscape, and identify potential growth areas within the global anti-infectives market. Use this report to assess anti-infective therapies that will be crucial to maintaining positive sales growth, analyze the marketed product portfolio and R&D pipelines of the leading 10 pharmaceutical companies in the global anti-infectives market.

The Women’s Health Market Outlook to 2011
With increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women’s health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes. ‘The Women’s Health Market Outlook to 2011’ is a new report providing analysis of the current and future market for women’s health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women’s health market. Key indications covered in this report are osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynecological infections.

Winning Product Launch Strategies Maximizing sales from new pharmaceutical products
With pharmaceutical R&D continuing to suffer from declining productivity levels and stagnant returns on investment, effective, flexible and commercially successful new product launches have become more important than ever. How pharma companies drive product uptake and the effectiveness of their competitive positioning during the launch phase increasingly define pharmaceutical market success. ‘Winning Product Launch Strategies’ is a new report featuring case studies of successful product launches of several key drugs. The results of 163 new product approvals and launches conducted across the US and EU are analyzed to provide up-to-date information on trends in new drug launches along with key factors for successful launches. Use this report to gain a comprehensive understanding of current and future product launch strategies, discover key differences between US and EU approaches and identify current best practices for successful product launch.

Indication Expansion Opportunities for successful lifecycle management
Due to shrinking pipelines and rising financial pressures on pharmaceutical companies, indication expansion is an increasingly attractive strategy to expand patient potential and extend market exclusivity. Indication Expansion is a new report that provides in-depth case studies analyzing successful recent indication expansions and emerging trends. This report will enable you to avoid potential pitfalls whilst gaining a comprehensive review of how to delay generic competition and boost revenue growth. Use the case studies in this report to identify best practice examples of indication expansion strategies and ensure that you can implement these into your current processes to maximize the lifecycle of your products.

The Dermatology Market Outlook to 2011
‘The Dermatology Market Outlook to 2011’ provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes. The in-depth 6-year epidemiology and product sales forecasts in this report will enable you to plan effectively, evaluate changes in the competitive positions of leading companies and accurately benchmark your position. The 5 Major dermatological indications covered are acne, psoriasis, infectious diseases of the skin, dermatitis, rosacea.

eHealth Solutions for Pharma Strategies for salesforces marketing patient compliance and clinical trials
The online channel offers a key opportunity for pharma companies to restructure their sales and marketing model, improving their relationships with physicians and increasing compliance among patients. At the same time, patients are demanding a greater role in treatment decisions and seeking information from a range of online sources, resulting in a new age of consumerism in healthcare. eHealth solutions for Pharma is a new report that provides an overview of the changing pharma market place, providing solutions on effective three way communication between pharmaceutical companies, patients and physicians. Online strategies such as eDetailing, eSampling, eCME and eCompliance are explored, enabling you to gain best practice advice on the opportunities offered by eHealth technologies. Use this report to identify ways to increase productivity and improve communications between your company, physicians and patients, and implement eHealth strategies to ensure your products achieve commercial success.

Future Growth Opportunities in Generics The impact of consolidation on market and competitive dynamics
The number of commercially lucrative drugs coming off patent has catalyzed the growth of the generics industry, creating significant profit opportunities for generics manufacturers. However, this market faces a considerable number of threats, with bulk manufacturers from developing countries becoming internationally competitive and the aggressive actions of branded pharmaceutical marketers in protecting their patent and market position resulting in ramifications for the sector as a whole. Future Growth Opportunities in Generics provides an in-depth analysis into the direction of the global generics market, evaluating competitive dynamics through a detailed review of major consolidation activity in the sector. Opportunities for future success are also explored, including the potential offered by biosimilars and the increasing focus by governments on healthcare cost containment, enabling you to determine the factors crucial to your success in the global generics market.

Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery
Drug delivery is one of the most dynamic and fast growing sectors of the pharmaceutical industry; the high level of innovation in this sector is evolving at a fast pace with products such as Pfizer’s inhaled insulin, Exubera, gaining US approval in January 2006. ‘Innovation in Drug Delivery’ provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal technologies. This report will enable you to evaluate key marketed drugs, including Emend and Megace, and gain an insight into novel pipeline products to anticipate upcoming product launches and position yourself for success. Use this report to understand how nanotechnology and other key technologies are changing drug delivery and how these can be implemented into your R&D process. Assess the impact of innovation in therapy areas including oncology, diabetes and infectious diseases and identify future opportunities for market growth.

Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition
Today, consumers are taking a more proactive approach to managing their health and the prevention of diet-related diseases, such as obesity, diabetes, cardiovascular and bone and joint diseases. Many of these diseases are at epidemic levels, and this combined with increasing patient power makes the prevention of these lifestyle diseases attractive markets for both the food and pharmaceutical industries to exploit. Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health. This report assesses the changing regulatory landscape in addition to how the strategies of leading ingredients, food, drinks and pharmaceutical companies are evolving in the new consumer health marketplace. Understand how food and drinks manufacturers are applying genomic and proteomic technologies that are widely used in the pharmaceutical industry in order to create increasingly sophisticated functional food products with this new report.

Innovations in CNS Novel therapeutics and future R&D strategies
The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status; pipelines based on novel molecular targets to treat underlying disease promise to transform the treatment of psychiatric and neurological diseases, however research and development of these drugs requires an innovative approach to ensure investment is maximized. ‘Innovations in CNS: Novel therapeutics and future R&D strategies’ assesses novel treatments in development for major CNS disorders, comparing them with existing medications in terms of unmet need and forecasting their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report provides a survey of the pipelines of all of the major players in the CNS area. Detailed company profiles featured in the report include: AstraZeneca, GlaxoSmithKline, Merck &Co, Pfizer, and Sanofi-Aventis. Use this report to understand the factors that will ensure your product pipeline achieves clinical and commercial success and analyze the product pipelines of the leading companies in the CNS market.

The Cardiovascular Market Outlook to 2011
The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market. This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin, and the development of new drug classes including Novartis’Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor. Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future.

Innovations in Cancer Novel therapeutics new diagnostics and future R&D strategies
The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology. These innovations will result in high value opportunities to develop newer and more effective therapies, ensuring companies can effectively respond to the increasing prevalence of cancer. ‘Innovations in Cancer’ provides a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and in-depth analysis of advances in both cancer therapeutics and diagnostics to provide a complete picture of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets. Use this report to understand how the cancer market is developing, identify areas of unmet medical need and align your product pipeline to achieve clinical and commercial success.

The Future of Metabolomics: Building competitive advantage in drug discovery
Metabolomics - the new ‘omics’ - is a dynamic and emerging field, joining genomics, transcriptomics and proteomics in enabling an integrative systems biology approach to drug discovery and development. Although metabolomics is still at an early evolutionary stage it is forecast that over the next decade the biopharma industry will apply this technology more widely in drug development and data obtained will be used in drug filing and optimizing the lifecycle management of marketed drugs.

The CNS Market Outlook to 2011
Psychiatric and neurological disorders constitute as much as 35%of the disease burden in the seven major pharmaceutical markets, representing continuing opportunities for pharma companies in the CNS market. However, the increasing presence of generic products coupled with low levels of innovative launches has resulted in a slowdown in market growth and considerable unmet need across the spectrum of CNS disorders. ‘The CNS Market Outlook to 2011’ provides comprehensive epidemiological analysis of the major CNS indications and key factors impacting market and competitive dynamics. This report will enable you to identify growth brands, key drug classes and leading companies through to 2011 ,pin-pointing market trends that will influence future sales of treatments within the CNS market. Evaluate changes in the competitive positions of the leading companies in the CNS market and ensure your R&D pipeline is aligned with future market opportunity to maximize commercial success.

The Cancer Market Outlook to 2011
Innovation is the key driving force in the cancer market, creating strong opportunities for biotech and pharma companies to launch new products and benefit from high volume sales and a strong competitive position. ‘The Cancer Market Outlook to 2011’ provides detailed analysis on 9 indications in the cancer market, identifying growth brands, key drug classes and leading companies. The 6-year epidemiology and product sales forecasts detailed in this report will enable you to evaluate the changes in the competitive positions of leading companies in the cancer market and ensure your R&D pipeline is aligned with future market opportunity to sustain revenue growth. Use this report to benchmark the strategies behind the market-leading products of today and identify which products will be best positioned for growth over the period 2006-2011.

The Specialty Pharma Market Outlook - Key players, new company growth models and emerging opportunities
While the specialty pharma sector has traditionally capitalized on opportunities from Big Pharma, competitive pressure and the maturing market is forcing them to develop new specialization strategies. These pressures, such as commoditization of drug delivery technologies and competition from foreign bulk generics manufacturers, are driving new company growth models and a focus on targeted portfolios, stronger late-stage drug development capabilities, M&A and in-licensing activity. ‘The Specialty Pharma Market Outlook ’evaluates current specialty pharma models, financial performance, core strategies and the future outlook of specialty pharma companies. This report also examines key specialty markets, providing valuable insights into market dynamics while profiling trends influencing market opportunities in therapeutic indications. Discover how leaders in the specialty pharma market are achieving high growth, benchmark your strategies against those of the industry ’s leaders and identify profitable partnering opportunities with the help of this new report.

Pharmaceutical Strategic Alliances - Maximizing returns from collaborative development and commercialization
In today’s competitive environment, alliances are critical for pharmaceutical companies to optimize R&D and marketing synergies and share risks in order to develop pipelines. Companies must maximize their licensing and alliance management capabilities in order to bring new drugs to the market successfully, while minimizing the potential for failure. ‘Pharmaceutical Strategic Alliances’ provides in-depth case studies focusing on deal outcomes, and highlights key success factors in agreeing and executing strategic alliances. The report isolates four key alliance structures - co-commercialization, co-development, multi-product and joint ventures - presenting a series of in-depth industry examples providing critical insights into current best practices and key recommendations for forming successful strategic alliances. Use this report to understand the complexities of the various types of strategic alliances, analyze the key issues and critical success factors behind building and managing effective alliances and ensure you negotiate the best deal terms for your company.

Innovations in Diagnostics - Next generation molecular and point-of-care diagnostics driving personalized healthcare
The global diagnostics market is undergoing radical change; novel technologies driven by miniaturization and advances in genomics will enhance the role of diagnostics in the healthcare market, allowing more tests to be performed at the point-of-care and facilitating the shift towards personalized medicine. “Innovation in Diagnostics” examines the advances in the rapidly growing field of molecular technologies that are enabling personalized healthcare to move into mainstream medicine. New opportunities in infectious disease testing, molecular oncology and pharmacogenomics are explored in detail, enabling you to understand the forces that are driving in vitro diagnostics (IVDs) into centre stage of the healthcare arena. Understand the changing relationship between IVD companies and the pharmaceutical industry, assess the convergence of IVDs and medical imaging, and develop an understanding of new technologies that will influence diagnostic product development and drug development programs.

Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
Positive economic growth, stabilizing political structures, growing patient populations and increasing direct foreign investment in the emerging markets of Brazil, Russia, India and China (BRIC) are creating significant opportunities for pharmaceutical companies to expand into these markets and maximize future revenue potential. Pharmaceutical sales across the BRIC economies grew by 22.3%in 2005, compared to single digit growth in the major markets of the US, Europe and Japan. This new report provides an in-depth insight into the competitive dynamics of the BRIC markets. The political and regulatory environments are evaluated and healthcare systems assessed, enabling you to understand the determinants crucial to your success in these high growth markets. Benchmark your growth strategies against the top pharmaceutical companies operating in the BRIC markets, align your portfolio with future market opportunity and identify lucrative partnering opportunities to ensure you maximize the potential from these promising markets.

Published: August 2006

The Future of Monoclonal Antibody Therapeutics - Innovation in antibody engineering, key growth strategies and forecasts to 2011
The market for therapeutic monoclonal antibodies (mAbs) is one of the most dynamic sectors within the pharmaceutical industry; next generation antibodies are forecast to drive the market towards the $30 billion mark by 2011 due to a high level of innovation in early-stage discovery and several potential nichebusters set to launch in the next 5 years. ‘The Future of Monoclonal Antibody Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011’ is a unique report that combines up-to-date analysis of the current antibodies market with detailed insights into therapeutic, technology, discovery and drug delivery trends set to shape the market in the next 5 years and beyond. Gain access to the most comprehensive data on the antibody market and take advantage of exclusive insights into research trends from early stage discovery to marketed drugs.

The Asthma, COPD & Allergic Rhinitis Market Outlook to 20011
The prevalence of asthma in 2005 across the US, Japan, France, Germany, Spain, Italy and the UK was estimated at 53.2m people, corresponding to a prevalence rate of 7.7%. The highest prevalence rate for asthma in any country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total prevalence of asthma across the seven major markets will be 58.8m sufferers or 8.0% of the population. COPD is only significantly prevalent in adults, a contrary situation to that of asthma, in which pediatric patients are estimated to represent some 35% of the total asthmatic patient population across the 7 major markets. 56.4m individuals are estimated to suffer from COPD across the seven major markets, although extremely low rates of diagnosis are thought to have resulted in a treated population of less than 10m individuals. Increasingly, COPD is becoming a major disease burden across the seven major markets, with a forecast patient population of 60.8m individuals by 2011, indicating high levels of future patient potential. Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients.